Disadvantages of Nanomedicine – Nanomedicine

Of course, there are valid arguments against the use of nanomedicine, particularly around the issue of toxicity. As explained in the Scientific American article Nano-risks: A Big Need for a Little Testing, Elements at these microscopic levels can exhibit different properties than they do normally. Furthermore, every nanoparticle is unique, and sometimes the effects or two of the same nanoparticles are not consistent. Thus, some nanoparticles might become dangerous for humans. It has been shown [Young and Martel, 2009] that even nanoparticles that naturally occur in our body can have a serious effect on both our short term and long term health. If these naturally created nanoparticles can harm us, then it would not be wise to proceed with using ones that are artificially engineered with first considering the possible effects and consequences. If nanomedicine was expanded to nanorobotics, then we would need to consider the possible effects of a glitch in the programming, and how sever the effects must be. This reminds us that before nanomedicine can be used extensively, it will need to go through a rigorous process of testing to make sure itdoesn'tdo more harm than good. Another disadvantage of nanotechnology is the enormous financial costs associated with it. As said in a report by the ETC group, Nanotech Rx, the global health crisisdoesn'tstem from a lack of science innovation or medical technologies; the root problem is poverty and inequality. New medical technologies are irrelevant for poor people if theyaren'taccessible or affordable. There is the problem that nanomedicine will definitely be too expensive for the average citizen, at least at first. It raises a question on whether we should focus instead on improving key aspects of the health system and providing better access to medicine and infrastructure I less developed countries. As the ETC says, access to clean water could make a greater contribution to global health than any single medical intervention. If we cant even maintain a working system using the current possibilities of medicine, should we start by fixing whats wrong before looking at something new, wasting billions of dollars in the process? Finally, nanomedicine, like all technology, can also be used for malicious purposes. Much of the proposed technology and treatment that nanomedicine will bring can be used for purposes other than originally intended. This leads to problems of ethics and privacy. Nanorobots that could monitor the level of insulin in people in diabetes could also be misused by government and corporations trying to increase surveillance of citizens. Such technology can also be used for military purposes. And where should we draw the line in the practical use of nanomedicine? To illustrate, if such technology allows us to heal people who have lost their vision or damaged their brain, either by an accident or through natural causes, should this technology be released to the general public, allowing people to have biotech implants that give them superior vision or mental abilities? Should this be extended to military purposes? If so, then to what extent? There are many moral and ethical dilemmas regarding nanomedicine that must be answered before this technology is put to use.

Follow this link:
Disadvantages of Nanomedicine - Nanomedicine

Euroscicon – Nanotech & Nanobiotechnology

About Conference

The EuroSciCon will be holding conference onNanotech & Nanobiotechnology 2018 which is scheduled duringJuly 12-13, 2018atParis, France. The theme of the conference isChallenges and Innovations in next generation Nanoscience".

The Nanobiotech 2018 aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Nanomedicine in Healthcare. It also provides the premier interdisciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered, and the solutions adopted in the field of Nanomedicine. The conference program will cover a wide variety of topics relevant to the Nanomedicine, including: Nanomedicine in drug discover and delivery, Nano diagnostics, theragnostic, applications of Nanomedicine in healthcare applications and disease treatments.

What's New

Nanotech & Nanobiotechnology 2018 includes international attendee workshops, lectures and symposia, including a designated registration area, a refreshment break and gala lunch. Nanotechnology educators can join the EuroSciCon as an international member to receive discounts on registration. So, come and join leading experts and allied professionals from July 12-13, 2018 in Paris, France to keep up with the rapidly accelerating pace of change that is already having an impact on the field of Nanotechnology, Nanomedicine & Nanobiotechnology and will continue to in the future. The field ofNanotechnologyhave not only helped the development in different fields in science and technology but also contributed towards the improvement of the quality of human life to a great extent. All this has become possible with the different discoveries and inventions leading to the development of various applications. The core aim of Nanotech & Nanobiotechnology 2018conference is to provide an opportunity for the delegates to meet, interact and exchange new ideas in the various areas of Nanotechnology andBiotechnology.

About Paris, France

Paris is the capital and most populous city of France. The city is both acommuneanddepartmentand forms the Centre and headquarters of theFrance, or Paris Region. By the 17th century, Paris was one of Europe's major centers of finance, commerce, fashion, science, and the arts, and it retains that position still today. The Paris Region had aGDPof 624 billion (US $687 billion) in 2012, accounting for 30.0 percent of the GDP of France. Paris is often referred to as "The City of Light" (La Ville Lumire), both because of its leading role during the Age of Enlightenment , and more literally because Paris was one of the first European cities to adopt gasstreet lighting. In the 1860s, the boulevards and streets of Paris were illuminated by 56,000 gas lamps. Since the late 19th century, Paris has also been known asPan-am.

Paris has many important cultural institutions: itsLouvremuseum is the most visited in the world; itsMuse d'Orsayis noted for its collection of FrenchImpressionistart, and its Pompidou-centerMuse National d'Art Modernehas the largest collection of modern and contemporary art in Europe. The central area of the city along the Seine River is classified as aUNESCO Heritage Siteand includes many notable monuments, includingNotre Dame Cathedral, theSainte-Chapelle, the formerUniversal ExpositionGrand Palais,Petit PalaisandEiffel Tower, and theBasilica of Sacr-CurinMontmartre. In 2015, Paris received 22.2 million visitors, making it one of the world's top tourist destinations.

Nanomedicine:

ToxicologyNanomedicineis a field of medical science whose applications are increasing more and more thanks tonanorobotsandbiological machines, which constitute a very useful tool to develop this area of knowledge. In the past years, researchers have done many improvements in the different devices and systems required to develop nanorobots. This supposes a new way of treating and dealing with diseases such as cancer; thanks to nanorobots, side effects of chemotherapy have been controlled, reduced and even eliminated, so some years from now, cancer patients will be offered an alternative to treat this disease instead of chemotherapy, which causes secondary effects such as hair loss, fatigue or nausea killing not only cancerous cells but also the healthy ones.

Nanoelectronics:

Nanoelectronics are based on the application of nanotechnology in the field of electronics and electronic components. Although the term Nanoelectronics may generally mean all the electronic components, special attention is given in the case of transistors. These transistors have a size lesser than 100 nanometers. Visibly, they are very small that separate studies must be made for knowing the quantum mechanical properties and inter-atomic design. As a result, though the transistors appear in the nanometer range, they are designed through nanotechnology. Their design is also very much different from the traditional transistors and usually falls in the category of one dimensional nanotubes/nanowires, hybrid molecular electronics, or advanced molecular electronics. This technology is said to be the next future, but its practicality is near to impossible even now that they may be difficult to emerge soon.

Nano architectonics:

The time for a major paradigm shift from nanotechnology to Nano architectonics has come. Scientists in nanoscience and nanotechnology have been creating fine nanomaterials and Nano systems using advanced physical techniques and apparatus, mainly as separate processes. These involve the fabrication of small objects and the observation of their behaviors. However, we are now must construct fine systems from these nanocomponents like the way that carpenters architect house and buildings. Technological efforts at the nanoscale must be organized and converted into the new concept of Nano architectonics

Nanophysics:

Nanotechnology is all about designing, fabricating and controlling materials and components with dimensions on the nanoscale, i.e. from 1 to 100 nm. During the Master's programme in Nanomaterials and Nanophysics you will learn how nanotechnology can be used in order to develop new optic and electronic components and new materials for use in communications technology, sensor technology or catalysis.

Nano mechanics:

The Nano mechanics investigates mechanical properties of engineered and biological materials at the Nano to macro-scale using experimental, analytical, and computational techniques. MEMS/NEMS (Microelectromechanical system/ Nanoelectromechanical system) devices are sensitive to a wide range of stimuli such as temperature, mass, pressure and are thus extensively used as sensors in cars and mobile phones. The biggest promise of MEMS and NEMS technology is the development of extremely small sensor systems that can be used virtually everywhere and thus can impart intelligence to almost all man-made things.

Nanorobotics:

A nanorobotics is a machine that can build and manipulate things precisely at an atomic level. Imaging a robot that can pluck, pick and place atoms like a kid plays with LEGO bricks, able to build anything from basic atomic building blocks. While some people dismiss the future of nanorobots as science fiction, you should realize that each of us is alive today because of countless nanobots operating within each of our trillions of cells. We give them biological names like a ribosome, but they are essentially machines programmed with a function like read messenger RNA to create a specific protein.

Nano chemistry:

Nano chemistry, described the field as "an emerging subdiscipline of solid-state chemistry that emphasizes the synthesis rather than the engineering aspects of preparing little pieces of matter with nanometer sizes in one, two or three dimensions. The Nano chemist can be considered to work towards this goal from the atom 'up', whereas the nanophysics tends to operate from the bulk 'down'." Today, Nano chemists work in biomedical chemistry, polymer chemistry, product synthesis, and a host of other areas. They use a wide variety of methods to prepare and assemble "little pieces of matter" with novel electronic, magnetic, optical, chemical, and mechanical behaviors that can be attributed to their nanometer-scale size.

Nanomaterials:

Nanotechnologies make use of very small objects or artifacts. Nanomaterials are an increasingly important product of nanotechnologies. They contain nanoparticles, smaller than 100 nanometers in at least one dimension. Nanomaterials are coming into use in healthcare, electronics, cosmetics and other areas. Their physical and chemical properties often they differ from those of bulk materials, so they call for specialized risk assessment. This needs to cover health risks to workers and consumers, and potential risks to the environment.

Cellular and subcellular Nanotechnology:

Cell biology today is on the verge of a nanotechnology-driven research era, one in which the availability of sophisticated new experimental techniques and tools of nanotechnology is set not only to emulate more complex,in vivolike extracellular environments, but also monitor dynamic complex biological processes in real time at the single cell level. Ultimately, the goal is to establish a fully integrated knowledge of how the building blocks of humans cells work at the molecular level. It is only by a detailed knowledge of how cells work, independently and together, in healthy and diseased states that one will be able to understand and anticipate the onset and effects of disease and create an appropriate and effective means to prevent and treat disease. The unravelling of cellular and molecular mechanisms that could be used to reprogram or instruct cells would enable unprecedented advances in tissue engineering and regenerative medicine.

Major Challenges in Nanobiotechnology:

Nanotechnology supporters believe that it has the potential to transform our lives dramatically, while opponents of nanotechnology fear that self-replicating "nanobots" could escape from laboratories and reduce all life on earth. Some ethical discussions have been focused on the field of molecular nanotechnology. The lack of meritorious ethics research proposals may be related to the difficulty in identifying or anticipating ethical issues that are unique to nanobiotechnology, particularly its near-term applications.

Advancement in Nanotechnology:

Advanced Nanotechnology was founded by industry visionaries to revolutionize systems and delivers a quantum improvement in performance, dramatically reduce power consumption and deliver extreme security. They use patented hardware and proprietary state-of-the-art algorithms to dramatically increases defense against hacking. We leverage the power of 3D & nanotechnology to break the semiconductor interconnect bottleneck and eliminate the gridlock that limits performance and waste power.

See the original post here:
Euroscicon - Nanotech & Nanobiotechnology

Nanorobots Market Segment Analysis by Types, Application and Outlook Forecast 2020-With Top Key Venders:Thermo Fisher,Ginkgo Bioworks,Oxford…

Report Hive Research releases a new study on Nanorobots Market which includes chapter wise data presentation, consisting multiple pages and hundreds of data Tables, Pie Chat, Graphs & Figures enclosed in the report.

The easy to understand detailed analysis demonstrates the present situation of market and also predicts its growth graph in upcoming future. For this, the researchers have made a complete assessment of the Market, before providing any estimations of the future trend.

The data is sourced from several attentive opinions, real facts and validated market data. The research study included in this report is influenced by our passion to help others excel in their businesses, so we do follow a strict consumer centric approach which allows us to produce high quality research reports

Key players discussed in the Nanorobots market report include the following big names:

BrukerJeolThermo FisherGinkgo BioworksOxford InstrumentsEv GroupImina TechnologiesToronto Nano InstrumentationKlocke NanotechnikKleindiek NanotechnikXidexSynthacePark SystemsSmaractNanonics ImagingNovascan TechnologiesAngstrom AdvancedHummingbird ScientificNt-Mdt Spectrum InstrumentsWitec

Nanorobots Segmentation by Product

NanomanipulatorBio-NanoroboticsMagnetically GuidedBacteria-Based

About Nanorobots

The global Nanorobots market size is estimated at xxx million USD with a CAGR xx% from 2015-2020 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Nanorobots by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Nanorobots Segmentation by Application

NanomedicineBiomedicalOthers

Market Trends: This includes the latest on-going trends driving Nanorobots market growth during the forecast timeframe. It can include elements such as technological advancements, and many other reasons triggering product demand.

Market Challenges/ RestraintsSimilar to a coin having two sides, the market includes unknown challenges as so it provides innumerable opportunities for growth. This section of the report allows our client to remain prepared, as market situations are seldom seen changing in quick succession. Apart from helping to realize the obstacles, the report also provides strategies to tackle these situations.

Market Drivers: Before entering a business, its always better to understand the audiences properly customers who will buy the products or services, ultimately driving in the revenue for which the businesses are built. So this section of market drivers sheds light on the major factors such as favourable government policies and any other reasons that should increase the product consumption during the forecast

Request a Sample Report @ https://reporthive.com/request_sample/2209146

Regions Covered: To better understand Nanorobots market dynamics, researchers have considered major global regions dominating the Nanorobots market share. All the regions are separately analysed before processing the big data acquired from across the globe. So, regional segmentation eases focusing on a particular region as per client interest. North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Report Customization: If the downloaded template is not as per your need, please connect with our sales team to initiate the process of report customization. We are always open to report customization, in case of special requirements or any specific segment or regions you want this report to be exclusively focussed on.

You may also request a customized PDF template through the link below: @ https://reporthive.com/checkout?currency=single-user-licence&reportid=2209146

Research Methodology:Our team of analysts incorporates both primary and secondary research methodologies to produce highly reliable data and growth assumptions for the future. Our data triangulation method includes analysis of several market scenarios and product mappings, which is then broken down into highly organized and statistical pre-sets.

Major Points Covered in Table Of ContentPart 1 Nanorobots Market Overview1.1 Nanorobots Market Definition1.2 Nanorobots Market Development1.3 Nanorobots By Type1.4 Nanorobots By Application1.5 Nanorobots By RegionPart 2 Global Nanorobots Market Status and Future Forecast2.1 Global Nanorobots Market by Region2.2 Global Nanorobots Market by CompanyPart 3 Asia-Pacific Nanorobots Market Status and Future Forecast3.1 Asia-Pacific Nanorobots Market by Region3.2 Asia-Pacific Nanorobots Market by TypePart 4 Asia-Pacific Nanorobots Market by Geography4.1 China Market Status and Future Forecast4.1.1 China Nanorobots Market by Type4.1.2 China Nanorobots Market by ApplicationPart 5 Europe Nanorobots Market Status and Future Forecast5.1 Europe Nanorobots Market by Region5.2 Europe Nanorobots Market by Type5.3 Europe Nanorobots Market by Application5.4 Europe Nanorobots Market by ForecastPart 6 Europe Nanorobots Market by Geography6.1 Germany Nanorobots Market Status and Future Forecast6.1.1 Germany Nanorobots Market by TypePart 7 Conclusion

About Us:Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Contact Us: Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: https://www.reporthive.comEmail: [emailprotected]Phone: +1 312-604-7084

View post:
Nanorobots Market Segment Analysis by Types, Application and Outlook Forecast 2020-With Top Key Venders:Thermo Fisher,Ginkgo Bioworks,Oxford...

Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors – Yahoo Finance

KANAZAWA, Japan, Feb. 10, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous system. The approach lies in combining two cancer drugs, with one compensating for a resistance side effect of the other.

In 20 40% of patients with cancer, metastasis (the development of secondary tumors) in the central nervous system (CNS) occurs. CNS metastatis impacts negatively on a patient's quality of life, and is associated with a poor health prognosis. In a form of cancer known as ALK-rearranged non-small-cell lung cancer (NSCLC), CNS metastatis is known to persist when drugs targeting primary tumors are used.Now, Seiji Yano from Kanazawa University and colleagues have investigated the origins for the resistence to such drugs, and tested a new therapeutic strategy on a mouse model.

The researchers looked at the drug alectinib.Although used in standard treatments for advanced ALK-rearranged NSCLC, approximately 20 30% of patients treated with alectinib develop CNS metastatis, which is attributed to acquired resistance to the drug.

By treating mice first injected with tumor cells with alectinib daily for 16 weeks, the scientists obtained a mouse model displaying alectinib resistance.By biochemical analyses of the mouse brains, Yano and colleagues were able to link the resistance to the activation of a protein known as epidermal growth factor receptor (EGFR).This activation is, in turn, a result of an increase in production of amphiregulin (AREG), a protein that binds to EGFR and in doing so 'activates' it.

Based on this insight, the researchers tested the effect of administering drugs used for inhibiting the action of EGFR in combination with alectinib treatment.The experiments showed that a combination treatment of alctinib with either erlotinib or osimertinib two existing EGFR-inibiting drugs prevented the progression of CNS metastasis, controlling the condition for over 30 days.

The scientists conclude that the combined use of alectinib and EGFR-inhibitors could overcome alectinib resistance in the mouse model of leptomeningeal carcinomatosis (LMC), a particular type of CNS metastasis.Quoting Yano and colleagues: "Our findings may provide rationale for clinical trials to investigate the effects of novel therapies dual-targeting ALK and EGFR in ALK-rearranged NSCLC with alectinib-resistant LMC."

Background

Non-small-cell lung cancer

Non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two types of lung cancer. 85% of all lung cancers are of the NSCLC type. NSCLCs are less sensitive to chemotherapy than SCLCs, making drug treatment of the highest importance.

Alectinib is a drug used for treating NSCLC, with good efficiency. However, 20-30% of patients taking the drug develop secondary cancer in the central nervous system (CNS), which is associated with an acquired resistance to alectinib.Seiji Yano from Kanazawa University and colleagues have now made progress towards a novel therapy against this resistance: a combination of alectinib with other drugs.

Epidermal growth factor receptor inhibitors

The drugs that Yano and colleagues tested in combination with alectinib on a mouse model were of a type known as epidermal growth factor receptor (EGFR) inhibitors, including osimertinib and erlotinib. Both are being used as medication for treating NSCLC.The former was approved in 2017 as cancer treatment by the U.S. Food and Drug Administration and the European Commission.Yano and colleagues obtained results showing that EGFR inhibitors counteract resistance to alectinib and have therefore potential in novel therapies for NSCLC and secondary cancers in the CNS.

Reference

Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-mei Zheng, Yi-Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, and Seiji Yano. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer, Journal of Thoracic Oncology, published online on January 21, 2020.

Story continues

DOI: 10.1016/j.jtho.2020.01.001

URL: https://www.sciencedirect.com/science/article/pii/S1556086420300228

About Nano Life Science Institute (WPI-NanoLSI)

https://nanolsi.kanazawa-u.ac.jp/en/

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Further information

Hiroe Yoneda Vice Director of Public Affairs WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University Kakuma-machi, Kanazawa 920-1192, Japan Email: nanolsi-office@adm.kanazawa-u.ac.jpTel: +81-(76)-234-4550

View original content:http://www.prnewswire.com/news-releases/kanazawa-university-research-combined-drug-treatment-for-lung-cancer-and-secondary-tumors-301001822.html

SOURCE Kanazawa University

Read more here:
Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance

Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead…

SALT LAKE CITY, Jan. 21, 2020 /PRNewswire/ --Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announcedits Australian subsidiary had completed enrollment and dosing of the first participant in the Phase 2 RESCUE-ALS study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The RESCUE-ALS study is substantially funded by FightMND.

"The objective of the randomized, double-blind RESCUE-ALS study is to demonstrate that improvements in brain bioenergetic cellular support in early symptomatic ALS patients treated with CNM-Au8 will help preserve motor neurons survival and function. The primary endpoint is the mean change in the average difference between active treatment and placebo from baseline through week 36 for the Motor Unit Number Index (MUNIX) score, which quantitatively reflects the loss of motor neurons in ALSthe primary cause of clinical progression in ALS," said Robert Glanzman, MD, FAAN, Clene's Chief Medical Officer.

"We are excited to advance CNM-Au8 clinically into this Phase 2 study for ALS patients," said Rob Etherington, President and CEO of Clene. "As neurodegenerative diseases such as ALS have very few treatment options, this study will prove whether CNM-Au8 may be an effective disease-modifying treatment for people with ALS."

"We are very excited to partner with Clene on the Phase 2 study in ALS, RESCUE-ALS," said Professor Steve Vucic, Director of Neurophysiology, Department of Neurology, at Sydney Medical School, Westmead Hospital. "CNM-Au8 offers an innovative approach of potentially treating neurodegenerative diseases, such as ALS, for which there are no effective treatments at present. We are hopeful that CNM-Au8 will be an effective therapy in the future and this trial will go a long way in addressing this question."

About RESCUE-ALS

RESCUE-ALS is Phase 2 multi-center randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic ALS (within 24-months of screening or 12-months from diagnosis) and with a clinically probable or possible or definite ALS diagnosis. Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 30 mg or placebo in addition to their current standard of care. Participants will receive their randomized oral treatment daily over 36 consecutive weeks during the Treatment Period. The treatment is taken by mouth once daily first thing every morning. The objective of this study is to assess bioenergetic catalysis with CNM-Au8 to slow disease progression in patients with ALS.

About CNM-Au8

CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted nanocrystalline gold (Au) that acts catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteersand both remyelination and neuroprotection effects in multiple preclinical models. Preclinical data presented at scientific congresses demonstrated that treatment with CNM-Au8 in neuronal cultures improved survival of neurons, protected neurite networks, decreased intracellular levels of reactive oxygen species, and improved mitochondrial capacity in response to cellular stress, induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in a rodent models of ALS, multiple sclerosis, and Parkinson's disease versus vehicle (placebo). CNM-Au8 has received regulatory approval to proceed to clinical studies for the treatment of remyelination failure in patients with multiple sclerosis and neuroprotection in patients with amyotrophic lateral sclerosis(ALS) and Parkinson's disease.

About Amyotrophic Lateral Sclerosis (ALS)

ALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About Clene

Clene Nanomedicine, Inc. is a privately-held, clinical-stage biopharmaceutical company, focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

About FightMND

FightMND is a not-for-profit registered charity, founded in 2014. It was established to raise the awareness of Motor Neurone Disease (MND) in Australia, to increase funding for research to find an effective treatment and cure and to provide care equipment for MND patients. We have a clear objective to a have a world free from MND.

FightMND is Australia's largest independent MND foundation focused on funding large- scale, collaborative research and clinical trials. The generous donations contributed by everyday Australians, right across the country, has enabled FightMND to raise and commit millions to cure and care initiatives.

Investor ContactKaitlyn BroscoThe Ruth Group646-536-7032 kbrosco@theruthgroup.com

Media Contact Kirsten ThomasThe Ruth Group508-280-6592 kthomas@theruthgroup.com

View original content:http://www.prnewswire.com/news-releases/clene-nanomedicine-announces-first-patient-dosed-in-the-rescue-als-clinical-trial-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-with-lead-nanocatalytic-therapeutic-cnm-au8-300989992.html

SOURCE Clene Nanomedicine, Inc.

See the original post:
Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead...

The Future Of Nano Medicine

Nanomedicine, refers to highly specific medical intervention at the molecular level for curing disease or repairing damaged tissues. Though in its infancy, could we be looking at the future of medicine? Early clinical trials certainly look promising.How Nanomedicine Works

- Nanomedicine works by injecting nanoparticles into the body- Can be used to:- Deliver medicine- Find and treat disease- Repair damaged cells

One human hair is approximately 80,000 nanometers wideApplications of Nanomedicine

- Drug Delivery- Using nanotechnology to deliver medicine, diabetic rats kept stable blood sugar levels for 10 days after injection- Cancer Diagnosis and Treatment- Using microRNA from a patient's blood plasma and nanotechnology:- Medical professionals can determine if lung cancer is present- Begin treatment the same day- Using Nano-Therm therapy to overheat brain cancer cells helps to destroy them- In clinical trials, those with recurrent glioblastoma survived a median of 13 months- More than double the survival rate of those not receiving Nano-Therm therapyNanotechnology is already commonly used in sunscreen and to make tennis balls more bouncy

- Flu Testing- Today's flu tests are:- Time consuming- Inaccurate- Nanomedicine gold flu testing provides:- Instant results- Immediate treatment cycle to avoid spreading to others- commercial nanotech testing no more than 5 years away- Cell Feedback- Nanomedicine can be used to test cell's response to drugs offering new drug testing methods- Provides instant feedback to how cells respond to medicine- Can save years and millions of dollars on testing and clinical trials- Can improve current medications

In a 1956, Arthur C. Clarke first envisioned the concept of nanotechnology in a short story, The Next TenantsAdvantages of Nanomedicine

- Faster diagnosis of many ailments- More precise treatments of conditions such as cancer- Repair tissue deep within the body- Target only diseased organs, lessening the need for drugsSources

- https://commonfund.nih.gov/nanomedicine/overview.aspx- http://www.understandingnano.com/medicine.html- http://pubs.acs.org/doi/abs/10.1021/nn400630x- http://www.nature.com/nnano/journal/v6/n10/full/nnano.2011.147.html- http://www.dana.org/news/features/detail_bw.aspx?id=35592- http://pubs.rsc.org/en/Content/ArticleLanding/2011/AN/C1AN15303J- http://onlinelibrary.wiley.com/doi/10.1002/smll.201001642/abstract- http://www.clinam.org/benefits.html

Original post:
The Future Of Nano Medicine

Nanomedicine Market to witness Huge Growth with Projected up to 2026 – Market Reports Observer

Latest release from SMI with title Nanomedicine Market Research Report 2019-2026 (by Product Type, End-User / Application and Regions / Countries) provides an in-depth assessment of the Nanomedicine including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. Global Nanomedicine Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released BY SMI. The report presents a complete assessment of the Market covering future trends, current growth factors, attentive opinions, facts, and industry-validated market data forecast until 2026.

Global Nanomedicine Market Segmentations

The segmentation chapter allows readers to understand aspects of the Global Nanomedicine Market such as products/services, available technologies, and applications. These chapters are written in a way that describes years of development and the process that will take place in the next few years. The research report also provides insightful information on new trends that are likely to define the progress of these segments over the next few years.

Download Free Sample Report with Latest Industry Trends 2019 @ https://www.stratagemmarketinsights.com/sample/9943(**Note: Free Sample with TOC, Graph, Charts)

Global Nanomedicine Market and Competitive Analysis

Know your current market situation! Not only an important element for new products but also for current products given the ever-changing market dynamics. The study allows marketers to stay in touch with current consumer trends and segments where they can face a rapid market share drop. Discover who you really compete against in the marketplace, with Market Share Analysis know market position, % market Share and Segmented Revenue of Nanomedicine Market

Segmentation and Targeting

Essential demographic, geographic, psychographic and behavioral information about business segments in the Nanomedicine market is targeted to aid in determining the features company should encompass in order to fit into the business requirements. For the Consumer-based market the study is also classified with Market Maker information in order to better understand who the clients are, their buying behavior and patterns.

*** For the global version, a list of below countries by region can be added as part of customization at minimum cost.North America (United States, Canada & Mexico)Asia-Pacific (Japan, China, India, Australia, etc)Europe (Germany, UK, France, etc)Central & South America (Brazil, Argentina, etc)Middle East & Africa (United Arab Emirates, Saudi Arabia, South Africa, etc)

Nanomedicine Product/Service Development

Knowing how the product/services fit the needs of clients and what changes would require to make the product more attractive is the need of an hour. Useful approaches to focus group by utilizing User Testing and User Experience Research. Demand-side analysis always helps to correlate consumer preferences with innovation.

Marketing Communication and Sales Channel

Understanding marketing effectiveness on a continual basis help determine the potential of advertising and marketing communications and allow us to use best practices to utilize an untapped audience. In order to make marketers make effective strategies and identify why the target market is not giving attention, we ensure the Study is Segmented with appropriate marketing & sales channels to identify potential market size by Revenue and Volume* (if Applicable).

Pricing and Forecast

Pricing/subscription always plays an important role in buying decisions; so we have analyzed pricing to determine how customers or businesses evaluate it not just in relation to other product offerings by competitors but also with immediate substitute products. In addition to future sales Separate Chapters on Cost Analysis, Labor*, production* and Capacity are Covered.

How geography and sales fit together

This study is helpful to all operators who want to identify the exact size of their target audience at a specific geographic location. Nanomedicine Market allows entrepreneurs to determine local markets for business expansion. This study answers the questions below:

1. Where do the requirements come from?2. Where do non-potential customers reside?3. What is the buying behavior of customers in a specific region?4. What is the spending power of the customers in a particular region?

** Enquire for customization in Report @ https://www.stratagemmarketinsights.com/quiry/9943

Having our reviews and subscribing our report will help you solve the subsequent issues:

*Uncertainty about the future: Our research and insights help our customers predict the upcoming revenue pockets and growth areas. This will guide customers to invest their resources.

*Understanding market sentiments: It is very important to have a fair understanding of market sentiment for your strategy. Our insights will help you see every single eye on market sentiment. We maintain this analysis by working with key opinion leaders on the value chain of each industry we track.

*Understanding the most reliable investment center: Our research evaluates investment centers in the market, taking into account future demand, profits, and returns. Clients can focus on the most prestigious investment centers through market research.

*Evaluating potential business partners: Our research and insights help our clients in identifying compatible business partners.

Furthermore, the years considered for the study are as follows:

Historical year 2013-2018Base year 2018Forecast period** 2019 to 2026 [** unless otherwise stated]

More Related Reports Click Here

This post was originally published on Market Reports Observer

Read the original post:
Nanomedicine Market to witness Huge Growth with Projected up to 2026 - Market Reports Observer

Nanomedicine Fact Sheet – National Human Genome Research …

Nanomedicine Overview

What if doctors had tiny tools that could search out and destroy the very first cancer cells of a tumor developing in the body? What if a cell's broken part could be removed and replaced with a functioning miniature biological machine? Or what if molecule-sized pumps could be implanted in sick people to deliver life-saving medicines precisely where they are needed? These scenarios may sound unbelievable, but they are the ultimate goals of nanomedicine, a cutting-edge area of biomedical research that seeks to use nanotechnology tools to improve human health.

Top of page

A lot of things are small in today's high-tech world of biomedical tools and therapies. But when it comes to nanomedicine, researchers are talking very, very small. A nanometer is one-billionth of a meter, too small even to be seen with a conventional lab microscope.

Top of page

Nanotechnology is the broad scientific field that encompasses nanomedicine. It involves the creation and use of materials and devices at the level of molecules and atoms, which are the parts of matter that combine to make molecules. Non-medical applications of nanotechnology now under development include tiny semiconductor chips made out of strings of single molecules and miniature computers made out of DNA, the material of our genes. Federally supported research in this area, conducted under the rubric of the National Nanotechnology Initiative, is ongoing with coordinated support from several agencies.

Top of page

For hundreds of years, microscopes have offered scientists a window inside cells. Researchers have used ever more powerful visualization tools to extensively categorize the parts and sub-parts of cells in vivid detail. Yet, what scientists have not been able to do is to exhaustively inventory cells, cell parts, and molecules within cell parts to answer questions such as, "How many?" "How big?" and "How fast?" Obtaining thorough, reliable measures of quantity is the vital first step of nanomedicine.

As part of the National Institutes of Health (NIH) Common Fund [nihroadmap.nih.gov], the NIH [nih.gov] has established a handful of nanomedicine centers. These centers are staffed by a highly interdisciplinary scientific crew, including biologists, physicians, mathematicians, engineers and computer scientists. Research conducted over the first few years was spent gathering extensive information about how molecular machines are built.

Once researchers had catalogued the interactions between and within molecules, they turned toward using that information to manipulate those molecular machines to treat specific diseases. For example, one center is trying to return at least limited vision to people who have lost their sight. Others are trying to develop treatments for severe neurological disorders, cancer, and a serious blood disorder.

The availability of innovative, body-friendly nanotools that depend on precise knowledge of how the body's molecular machines work, will help scientists figure out how to build synthetic biological and biochemical devices that can help the cells in our bodies work the way they were meant to, returning the body to a healthier state.

Top of page

Last Updated: January 22, 2014

See the rest here:
Nanomedicine Fact Sheet - National Human Genome Research ...

Nanomedicine | Ardena

This fast-evolving field uses nanoscale or nanostructured materials to impart unique pharmacokinetic and therapeutic effects such as enhanced dissolution rate and oral bioavailability, targeted delivery, enhanced efficacy and reduced toxicity.

The control of materials in the nanometer size range requires scientifically demanding chemistry, analysis and manufacturing techniques. Our nanomedicine expertise encompasses formulation, process and analytical development, GMP manufacturing and dossier development.

We are experts in the following formulations:

Once we identify a suitable formulation, our scientists develop phase-appropriate production processes in accordance with cGMP and mitigate technology transfer issues by using the same teams for development and manufacturing.

Techniques include:

In our cGMP-compliant manufacturing facilities, we can produce volumes of a couple of millilitres to multiple litres, using batch-type and continuous-flow processes. We also work with highly-potent drug substances and can deliver nanosuspensions and nanoparticle solutions as sterile finished drug products in vials or syringes.

To support product development and to perform quality control of GMP-produced drug products, we utilise state-of-the-art analytical techniques such as:

Having advanced a wide range of nanomedicine formulations into the clinic, we are used to developing new manufacturing techniques and analytical procedures under fierce regulatory scrutiny. Our understanding of the regulatory landscape gives your nanomedicine project the greatest chance of approval.

See more here:
Nanomedicine | Ardena

I believe in Renewable Energy, and here’s why

Renewable energy (RE) is a subjective and divisive topic, one that is influenced by many factors, including corruption, greed and purposeful ignorance, scientific and technological advances, and simple entrepreneurial spirit vs. entrenched interests.

Here are some of the reasons that I believe that we will see RE replace old energy by the midpoint of this century:

* It has been estimated that an area 55 miles by 55 miles dedicated to current solar technologies could replace all the electrical generating power of coal and oil (in the US). Or an area 80x80 miles to replace oil, coal and natural gas. (Here in the US we have over 100,000 square miles of desert, so space isn’t a problem)

* Regarding storage technologies (1) for when the sun is down: consider the advances taking place in fuel cells, batteries (LI, redox flow batteries, and 1300-ton battery modules used for grid stabilization), flywheels, compressed air, ultracapacitors and the likelihood that we will also use battery powered vehicles as storage.

* Regarding “getting the power from the solar installation to the people” – consider advances in superconducting wire and other advanced materials which are very likely to enable cheap and efficient transmission of power from where ever it is generated to where ever it is needed.

* Rooftop and local solar: My solar powered home won’t have to worry about darkness; we’ll tap into the battery reserve, as will all rooftop solar installations. A small percentage of our overall use to be sure, but significant none the less.

And as for explicit subsidies: on a per-energy-unit basis, then yes, solar has received more subsidies than fossil fuels in the very recent past. However, on the amount that each of us taxpayers has spent in a recent five-year period, fossil fuels subsidies far exceed solar.

Estimates range: (2)

Coal subsidies = somewhere between $17B and $72B
Solar subsidies = somewhere between $500M and $5B

And let us not forget that coal subsidizes also include intangible (and often purposefully left out) costs for cleaning up the ecosystem, and the public health expenses associated with all of the damage that the mining and use of coal causes. (3)

In my opinion, at the end of the day it all boils down to two simple facts: 1) technological change is on a double exponential growth curve (4) and 2) simple entrepreneurial spirit.

While we certainly need to wean society off finite, dangerous, polluting resources like coal and oil, the earth can and may go to hell in a handbasket. However, I think that entrepreneurial spirit and the certain fact that there is a barrel of money to be made in renewable energy solutions suggests that we will see RE replace old energy by the midpoint of this century. (5)

(1) "Of the ten advanced energy storage technologies, eight have applications in storage for electric power utilities at some level of development, aiming to provide reliable, economic, and energy-efficient power back-up options." Technical Insights Analyst Miriam Nagel

A123 Systems currently sells 2MW to 200MW grid stabilization systems (battery systems). Being used for large-scale energy storage deployment to support wind and solar integration. Small in comparison to the overall needs, but just one of many rapidly improving technologies.

“If investments in the smart grid infrastructure continue, electric vehicles may become ubiquitous — both because of the economic and environmental sense they make for consumers, and because of the vast store of batteries that will be available to grid operators to balance out the intermittency of wind and solar resources.”

“There are several major studies and research showing how the United States could reach 100 percent renewable electricity by 2050. Over the next two decades, the continually rising costs of fossil fuels will make it prohibitive to continue burning them, so we’ll witness the overdue transition to a largely renewable system. Smart grid upgrades will feature two-way communication to consumer appliances, real-time pricing information, more efficient transmission infrastructure, and advanced battery and flywheel technologies to balance the inherent fluctuations of wind and solar resources.”

http://www.mnn.com/earth-matters/energy/blogs/quayle-hodek-a-young-ceo-running-with-the-wind?hpt=Sbin

(2) “What if solar got the same subsidies as coal?” (Oct 21, 2010)
http://cleantechnica.com/2010/10/21/what-if-solar-got-the-same-subsidies-as-coal/

Coal subsidies: The U.S. coal industry enjoyed subsidies of around $17 billion between 2002 and 2008, including tax credits for production of "nonconventional" fuels ($14.1 billion), tax breaks on coal royalties ($986 million), exploration, and development breaks ($342 million), according to a study by the Environmental Law Institute.

http://sierraclub.typepad.com/mrgreen/2010/03/does-the-coal-industry-get-subsidies.html

Solar and wind subsidies: So far, the government has handed out about $5.4 billion, according to the Energy Department.

http://money.cnn.com/2010/11/18/news/economy/renewable_energy_tax_credit/index.htm

(3) Very informative investigative article http://wonkroom.thinkprogress.org/2011/02/03/manchin-coal-subsidies/

(4) “Most long range forecasts of technical feasibility in future time periods dramatically underestimate the power of future technology because they are based on what I call the “intuitive linear” view of technological progress rather than the “historical exponential view.” To express this another way, it is not the case that we will experience a hundred years of progress in the twenty-first century; rather we will witness on the order of twenty thousand years of progress (at today’s rate of progress, that is).” Ray Kurzweil http://www.kurzweilai.net/the-law-of-accelerating-returns

(5) During the past 11 years, as the editor of the leading nanoscale technologies web portal, I read and posted over 50,000 articles about advanced and frequently mind-blowing technologies. I have closely followed the very rapid progress in our understanding and utilization of the unique properties of the nanoscale (which greatly differ from the properties that we already understand). At the very least, we are headed for a future that not one of us can predict; what we can predict is that we will undoubtedly see old myths about technologies shattered and changes beyond our current level of comprehension.

Home [www.clinam.org]

CLINAM 9 / 2016 Conference and Exhibition

European & Global Summit for Cutting-Edge Medicine

June 26 29, 2016

Clinical Nanomedicine and Targeted Medicine -

Enabling Technologies for Personalized Medicine

Scientific Committee: Chairman Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH). MEMBERS Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL). Dr. med. h.c. Beat Ler, MA, European Foundation for Clinical Nanomedicine, Basel (CH) Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (UK). Prof. Dr. med. Christoph Alexiou, University Hospital Erlangen (D) Prof. Dr. Gerd Binnig, Nobel Laureate, Munich (DE) Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zrich (CH). Prof. Dr. Jan Mollenhauer, Lundbeckfonden Center of Excellence NanoCAN, University of Southern Denmark, Odense (DK). Prof. Dr. med. Omid Farokhzad, Associate Professor and Director of Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital; Founder of BIND Therapeutics, Biosciences and Blend Therapeutics, Cambridge, Boston (USA) Prof. Dr. Dong Soo Lee, M.D. Ph. Chairman Department of Nuclear Medicine Seoul National University Seoul, Korea (invited) Prof. Dr.Lajos Balogh, Editorin in Chief, Nanomedicine, Nanotechnologyin, Biology and Medicine, Elsevier  and Member  of theExecutive Board, American Society for Nanomedicine in, Boston(USA) and other members.

Conference Venue: Congress Center, Messeplatz 21, 4058 Basel, Switzerland, Phone + 41 58 206 28 28, This email address is being protected from spambots. You need JavaScript enabled to view it. Organizers office: CLINAM-Foundation, Alemannengasse 12, P.B. 4016 Basel Phone +41 61 695 93 95, This email address is being protected from spambots. You need JavaScript enabled to view it.

In the previous eight years, the CLINAM Summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy from over 40 different countries in Europe and worldwide. With this success and broad support by well beyond 20 renowned collaborating initiatives, the CLINAM-Summit is today one of the most important marketplaces for scientific exchange and discussions of regulatory, political and ethical aspects in this field of cutting edge medicine.

In particular, the CLINAM Summit emerged as exquisite forum for translation from bench to bedside, for European and international networking, and for industrial collaboration between companies, with academia, and point-of-contact with customers. The summit is presently the only place to meet the regulatory authorities from all continents to debate the needs of all stakeholders in the field with the legislators.

CLINAM 9/2016continues with its successful tradition to cover the manifold interdisciplinary fields of Clinical and Targeted Nanomedicine in major and neglected diseases. As special focus area, CLINAM 09/2016 adds translation and enabling technologies, including, for example, cutting-edge molecular profiling, nano-scale analytics, single cell analysis, stem cell technologies, tissue engineering, in and ex vivo systems as well as in vitro substitute systems for efficacy and toxicity testing.

CLINAM 09/2016covers the entire interdisciplinary spectrum of Nanomedicine and Targeted Medicine from new materials with potential medical applications and enabling technologies over diagnostic and therapeutic translation to clinical applications in infectious, inflammatory and neurodegenerative diseases, as well as diabetes, cancer and regenerative medicine to societal implications, strategical issues, and regulatory affairs. The conference is sub-divided into four different tracks running in parallel and provides ample possibilities for exhibitors as indicated by steadily increasing requests:

Track 1: Clinical and Targeted Nanomedicine Basic Research Disease Mechanisms and Personalized Medicine Regenerative Medicine Novel Therapeutic and Diagnostic Approaches Active and Passive Targeting Targeted Delivery (antibodies, affibodies, aptamers, nano drug delivery devices) Accurin Technology Nano-Toxicology Track 2: Clinical and Targeted Nanomedicine: Translation Unsolved Medical Problems Personalized Medicine and Theranostic Approaches Regenerative Medicine Advanced Breaking and Ongoing Clinical Trials Applied Nanomedical Diagnostics and Therapeutics Track 3: Enabling Technologies Nanomaterial Analytics and Testing Molecular Profiling for Research and Efficacy/Toxicology Testing (Genomics, Proteomics, Glycomics, Lipidomics, Metabolomics) Functional Testing Assays and Platforms Single Cell Analyses Cell Tracking Stem Cell Biology and Engineering Technologies Microfluidics Tissue Engineering Tissues-on-a-Chip Bioprinting In vivo Testing Novel Imaging Approaches Medical Devices Track 4: Regulatory, Societal Affairs and Networking Regulatory Issues in Nanomedicine Strategy and Policy The Patients` Perspective Ethical Issues in Nanomedicine University Village Cutting-Edge EU-Project Presentations Networking for International Consortium Formation

For CLINAM 9 / 16 Last Summit the number of exhibitors increased without investment of acquisition.As from the 9th Summit the CLINAM-Foundation has stepped in to a Partnership with The Congress Center Basel which will invest in a proactive acquisition and management for large foyer exhibition. Based on last years exhibition it is expected to have about 50 Exhibitors at thenext Summit. Exhibitors can profit of the possibility to meet their target visitors on one single spot in Basel at CLINAM 9 / 2016. With this new concept for the exhibition, the international CLINAM-summit becomes also the place for the pulse of the market and early sales in the field of cutting-edge medicine.

The exhibitors are invited to participate in the below in the nomenclature described fields. The list is topic to extensions so that by proposals from exhibitors it will constantly be updated. Strong focus of the exhibition relates to the topics of the conference in which Nanomedicine and Targeted Medicine - presently the most important building blocks in novel Medicine - are debated. The organizers look forward to the interest of the exhibitors to at a moderate investment take the opportunity to meet the community of Nanomedicine, Targeted Medicine and those investing into cutting edge Medicine tools and applications.

The CLINAM- Summit has every year 150 presentations. Many young mist skilled young researchers, young starting entrepreneurs, Engineers and scientists apply for posters and oral presentations. CLINAM offers a first Deadline for those, submitting their work before February 15, 2016 a discount of 20% on the registration fees for Submitters (610.00 ; for students 430.00 ) . The second Deadline after that is April 25, 2016

The Exhibitors at CLINAM 8/2015

The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.

Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimeter. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.

More here:
Home [www.clinam.org]

Nano-Medicine – Wild Iris Design

Introduction Background Basics Nano-Computing Utility Fog Nano-Medicine The Downside Comments Sources

Nano-Medicine

Nanocomputers are small enough that several hundred of them could fit inside the space of a biological cell. Medical nanites could patrol your body, and armed with knowledge of your DNA, repel any foriegn invaders by forming an artificial immune system. The common cold would no longer exist, nor would threats of any biological or viral infection. Biological warfare would then cease to be a threat, also.

These nanites, composed of smart materials, could take over from the plastic surgeons and people would be able to remake their bodies, even change their sex if that was what they wanted to do. There would be no pain, no bruises, and the results would be overnight. Additionally, imagine your body and bones woven with invisible diamond fabric. This body "reinforcement" could increase your tolerance to "G" forces, enable you to fall from a 10 story building and walk away, replace the oxygen in your blood in case of fire or chemical spill, and allow you to walk away from normally fatal accidents.

Life consists of molecular machines controlled by a program (DNA). Aging is a disease and is the real number one killer of humans. With the new genetic therapies it is hoped that the aging process can be reversed within the next 12 to 20 years. With medical nanites, we can not only extend our lives but stop completely the aging process.

valerie@wildirisdesign.com

Link:
Nano-Medicine - Wild Iris Design

IBMs nanomedicine initiative – IBM Research: Overview

Creating a hydrogel from the polymers

Through the precise tailoring of the ninja polymers, researchers were able to create macromolecules - molecular structures containing a large number of atoms - which combine water solubility, a positive charge, and biodegradability. When mixed with water and heated to normal body temperature, the polymers self-assemble, swelling into a synthetic hydrogel that is easy to manipulate.

When applied to contaminated surfaces, the hydrogel's positive charge attracts negatively charged microbial membranes, like stars and planets being pulled into a black hole. However, unlike other antimicrobials that target the internal machinery of bacteria to try to prevent it from replicating, this hydrogel destroys the bacteria by rupturing the bacteria's membrane, rendering it completely unable to regenerate or spread.

The hydrogel is comprised of more than 90 percent water, making it easy to handle and apply to surfaces. It also makes it potentially viable for eventual inclusion in applications like creams or injectable therapeutics for wound healing, implant and catheter coatings, skin infections or even orifice barriers. It is the first-ever to be biodegradable, biocompatible and non-toxic, potentially making it an ideal tool to combat serious health hazards facing hospital workers, visitors and patients.

The IBM scientists in the nanomedicine polymer program along with the Institute of Bioengineering and Nanotechnology have taken this research a step further and have made a nanomedicine breakthrough in which they converted common plastic materials like polyethylene terephthalate (PET) into non-toxic and biocompatible materials designed to specifically target and attack fungal infections.BCC Research reported that the treatment cost for fungal infections was $3 billion worldwide in 2010 andis expected to increase to $6 billion in 2014. In this breakthrough, the researchers identified a novel self-assembly process for broken down PET, the primary material in plastic water bottles, in which 'super' molecules are formed through a hydrogen bond and serve as drug carriers targeting fungal infections in the body. Demonstrating characteristics like electrostatic charge similar to polymers, the molecules are able to break through bacterial membranes and eradicate fungus, then biodegrade in the body naturally. This is important to treat eye infections associated with contact lenses, and bloodstream infections like Candida.

See the article here:
IBMs nanomedicine initiative - IBM Research: Overview

Nano Medicine

May 31st, 2015 Filed under Urology Research Tagged beaumont, bladder, chinese, education, health, inter-, interstim, ministrelli, spinal, united, urology Comments Off on Urology Research William Beaumont Hospital

Urology research at Beaumont Hospitals is on the cutting edge of clinical practice, aimed at bringing innovative research protocols to patient care, advancing the treatment of disease, improving patient outcomes and enhancing their quality of life. Known as a leader in the field, the department is involved in several innovative studies including interstitial cystitis, urinary incontinence and the prostate gland.

Research projects concentrate on developing novel treatments for urinary incontinence, overactive bladder, pelvic pain, prostate cancer, female reconstructive surgery and neurogenic bladder. These translational and clinical studies along with sponsored pharmaceutical and equipment/device trials offer the opportunity to treat disease states that traditional therapies fail to address. Funded through grants from the National Institutes of Health (NIH), philanthropy including the Ministrelli Program for Urology Research and Education (MPURE), and industry contracts, Beaumont physicians serve as the principal investigators in these national and international trials.

Studies on neuro-urology and incontinence identify and utilize novel therapies such as neuromodulation and nerve re-routing to treat men, women and children who have voiding problems demonstrated to be refractory to standard therapies.

Beaumont Hospitals launched a research study to rewire nerves in the spinal cord in the hope of giving bladder control to people with spinal cord injury or spina bifida who otherwise depend on self-catheterization to urinate. The first procedure garnered national attention and appeared in more than 160 news outlets including U.S.News and World Report, The Washington Post and Forbes. Beaumont is the only institution in the United States to perform this procedure and also provide funding for all the associated costs.

The research at Beaumont uses nerve rerouting to redirect nerves in the spinal cord to gain better control of urination. After the procedure, patients signal the bladder to urinate by scratching or pinching their leg or buttocks. The Chinese doctor who developed the surgery, Chuan-Guo Xiao, M.D., reports an almost 90-percent success rate. The average time it took to see results was 12 to 24 months after surgery, with patients in China reporting better urinary control and improvements in their bowel function.

Beaumont Hospital urologists are first in the United States to research stress urinary incontinence treatment using a persons own stem cells. The stem cells are used to strengthen weak muscles that control urination. If successful, (autologous) muscle-derived stem cell therapy could offer new hope to people and offer them a life free of urinary leakage, says Dr. Peters, who is leading the research at Beaumont. Stress urinary incontinence the cause of wetness with coughing or physical activity affects about 13 million Americans, most of them women, but also men who have had a prostatectomy (surgery for prostate cancer). Current treatments, including medicine, exercises and surgery, are not always effective and may have undesirable side effects. The stem cells from 48 female research participants age 18 or older will be collected at Beaumont Hospital, Royal Oak, and duplicated. The cells will then be injected into the muscles that control urination to strengthen them and prevent leakage.

Participation will last 12-14 months, and will include physical exams, procedures to assess the bladder, completing voiding diaries and questionnaires and a variety of diagnostic tests. A small sample of the participants thigh muscle will be collected, which is the source of the stem cells. Pregnant or nursing women may not participate.

The InterStim a pacemaker-like device used for urinary frequency, urgency and incontinence, is showing promise for treatment of interstitial cystitis symptoms. With the InterStim Therapy, manufactured by Medtronic, Inc., a small electrode is placed adjacent to the sacral nerve. The electrode is externalized and patients monitor their urinary urgency, frequency and pain for two weeks. If the symptoms are at least 50 percent improved, the stopwatch-size power generator is implanted in the upper part of the buttock. The generator is then connected to the previously-placed lead. When the generator produces a small electrical pulse, it stimulates the sacral nerve, helping to control the bladder, sphincter and pelvic floor.

In addition to stimulating the sacral nerve, Urology chairman Kenneth Peters, M.D., is conducting a research study looking at pudendal nerve stimulation using the InterStim device. Thirty subjects were implanted with both sacral and pudendal nerve electrodes. Patients tested each electrode in a blinded fashion. Seventy nine percent of subjects chose the pudendal lead as superior for treating their voiding dysfunction.

Read more:
Nano Medicine

Nanomedicine, bionanotechnology | NanomedicineCenter.com

A lot of patients suffering from colon cancer might well present no symptoms or signs during the earliest stages of the condition. When symptoms do eventually present, they can be many and varied, and can very much depend upon the size of the affliction, how far it has spread and also its actual location. It might be that some symptoms that present are as a result of a condition other than cancer itself, ranging from irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and occasionally diverticulosis. Also, such problems as abdominal pain or swelling can be symptomatic of colon problems and may well require further investigation.

You may also notice that, upon going to the lavatory, you have some blood in your stools, and this can be a symptom of cancer. Of course, having black poop doesnt ultimately mean that cancer is present. It can, however, also be indicative of other conditions and problems. For example, the kind of bright red blood that you may see on your toilet tissue could be as a result of hemorrhoids or anal fissures. It should also be remembered that various food items can also result in red poop, and these include beetroot and red liquorice. Some medications can also be culprits, and some can also turn the stools black-including iron supplements. Irrespective, any sign of blood or change in your stools should prompt you to seek advice from your GP, as it is always best to be sure that it is not a sign of a more serious condition, and with any cancer,early detection and treatment is essential to a successful recovery.

You should also note-if you are currently concerned-any change in the regularity of your stools-including whether or not they are more thin or irregular than usual-especially over a period of several weeks. Also, be mindful if you have diarrhea for several days in a row or, conversely, constipation.

You might also experience pain in your lower abdomen-including a feeling of hardness. You may also experience persistent pain or discomfort in your abdominal region, and this can include wind and cramps. You may also get the sensation that, when evacuating your bowels, that the bowel doesnt empty fully. Another symptom that you might recognize is colored stool mainly black stool, but could be green stool too. Also, if you have an iron deficiency (or anemia), it may be an indication that there is bleeding in your colon. Also, as in most cases and types of cancer, you should seek medical advice immediately if you experience any sudden and unexpected or unexplained weight loss, as this is one of the principal red flags. Also be aware of more vague, seemingly incidental symptoms, such as fatigue. IF you have a couple of symptoms and also feel fatigued for days in a row inexplicably, then this is also another warning sign and you should seek medical advice. It is important not to panic, but just to be aware of what might be going on.

Remember, cases of colon cancer account for around 90% of all cases of intestinal cancers, and also account for more deaths every year of men and women from cancer. Early treatment is an absolute must.

Read the rest here:
Nanomedicine, bionanotechnology | NanomedicineCenter.com

www.futuremedicine.com

This site uses cookies to improve performance. If your browser does not accept cookies, you cannot view this site.

There are many reasons why a cookie could not be set correctly. Below are the most common reasons:

This site uses cookies to improve performance by remembering that you are logged in when you go from page to page. To provide access without cookies would require the site to create a new session for every page you visit, which slows the system down to an unacceptable level.

This site stores nothing other than an automatically generated session ID in the cookie; no other information is captured.

In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a website to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it.

Read more here:
http://www.futuremedicine.com

Nanomedicine – Wikipedia, the free encyclopedia

Nanomedicine is the medical application of nanotechnology.[1] Nanomedicine ranges from the medical applications of nanomaterials, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials (materials whose structure is on the scale of nanometers, i.e. billionths of a meter).

Functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. The size of nanomaterials is similar to that of most biological molecules and structures; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical research and applications. Thus far, the integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug delivery vehicles.

Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices in the near future.[2][3] The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging.[4] Nanomedicine research is receiving funding from the US National Institutes of Health, including the funding in 2005 of a five-year plan to set up four nanomedicine centers.

Nanomedicine is a large industry, with nanomedicine sales reaching $6.8 billion in 2004, and with over 200 companies and 38 products worldwide, a minimum of $3.8 billion in nanotechnology R&D is being invested every year.[5] In April 2006, the journal Nature Materials estimated that 130 nanotech-based drugs and delivery systems were being developed worldwide.[6] As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.

Nanotechnology has provided the possibility of delivering drugs to specific cells using nanoparticles.

The overall drug consumption and side-effects may be lowered significantly by depositing the active agent in the morbid region only and in no higher dose than needed. Targeted drug delivery is intended to reduce the side effects of drugs with concomitant decreases in consumption and treatment expenses. Drug delivery focuses on maximizing bioavailability both at specific places in the body and over a period of time. This can potentially be achieved by molecular targeting by nanoengineered devices.[7][8] More than $65 billion are wasted each year due to poor bioavailability.[citation needed] A benefit of using nanoscale for medical technologies is that smaller devices are less invasive and can possibly be implanted inside the body, plus biochemical reaction times are much shorter. These devices are faster and more sensitive than typical drug delivery.[9] The efficacy of drug delivery through nanomedicine is largely based upon: a) efficient encapsulation of the drugs, b) successful delivery of drug to the targeted region of the body, and c) successful release of the drug.[citation needed]

Drug delivery systems, lipid- [10] or polymer-based nanoparticles,[11] can be designed to improve the pharmacokinetics and biodistribution of the drug.[12][13][14] However, the pharmacokinetics and pharmacodynamics of nanomedicine is highly variable among different patients.[15] When designed to avoid the body's defence mechanisms,[16] nanoparticles have beneficial properties that can be used to improve drug delivery. Complex drug delivery mechanisms are being developed, including the ability to get drugs through cell membranes and into cell cytoplasm. Triggered response is one way for drug molecules to be used more efficiently. Drugs are placed in the body and only activate on encountering a particular signal. For example, a drug with poor solubility will be replaced by a drug delivery system where both hydrophilic and hydrophobic environments exist, improving the solubility.[17] Drug delivery systems may also be able to prevent tissue damage through regulated drug release; reduce drug clearance rates; or lower the volume of distribution and reduce the effect on non-target tissue. However, the biodistribution of these nanoparticles is still imperfect due to the complex host's reactions to nano- and microsized materials[16] and the difficulty in targeting specific organs in the body. Nevertheless, a lot of work is still ongoing to optimize and better understand the potential and limitations of nanoparticulate systems. While advancement of research proves that targeting and distribution can be augmented by nanoparticles, the dangers of nanotoxicity become an important next step in further understanding of their medical uses.[18]

Nanoparticles can be used in combination therapy for decreasing antibiotic resistance or for their antimicrobial properties.[19][20][21] Nanoparticles might also used to circumvent multidrug resistance (MDR) mechanisms.[22]

Two forms of nanomedicine that have already been tested in mice and are awaiting human trials that will be using gold nanoshells to help diagnose and treat cancer,[23] and using liposomes as vaccine adjuvants and as vehicles for drug transport.[24][25] Similarly, drug detoxification is also another application for nanomedicine which has shown promising results in rats.[26] Advances in Lipid nanotechnology was also instrumental in engineering medical nanodevices and novel drug delivery systems as well as in developing sensing applications.[27] Another example can be found in dendrimers and nanoporous materials. Another example is to use block co-polymers, which form micelles for drug encapsulation.[11]

Polymeric nano-particles are a competing technology to lipidic (based mainly on Phospholipids) nano-particles. There is an additional risk of toxicity associated with polymers not widely studied or understood. The major advantages of polymers is stability, lower cost and predictable characterisation. However, in the patient's body this very stability (slow degradation) is a negative factor. Phospholipids on the other hand are membrane lipids (already present in the body and surrounding each cell), have a GRAS (Generally Recognised As Safe) status from FDA and are derived from natural sources without any complex chemistry involved. They are not metabolised but rather absorbed by the body and the degradation products are themselves nutrients (fats or micronutrients).

The rest is here:
Nanomedicine - Wikipedia, the free encyclopedia

IGERT Nanomedicine at Northeastern University

STUDENT SPOTLIGHT

IGERT HIGHLIGHT

NU IGERT Nanomedicine Program on YouTube!

Take a tour with three former IGERT trainees, Brian Plouffe, Tatyana Chernenko and Yogesh Patel, to hear about some of the outstanding research that is done in the IGERT Nanomedicine program at Northeastern.

MISSION

IGERT Nanomedicine Science and Technology is a new integrated doctoral education program in the emerging field of Nanomedicine, created with support from the National Cancer Institute and the National Science Foundation. The program aims to educate the next generation of scientists and technologists with the requisite skill sets to address scientific and engineering challenges, with the necessary business, ethical and global perspectives that will be needed in the rapidly emerging area of applying nanotechnology to human health.

The program began at Northeastern University in 2005 with an NSF IGERT grant funded through the National Cancer Institute. The success of the program has since then led to an NSF funded IGERT renewal grant for the period 2010-2015 with new partners, Tuskegee University, The University of Puerto Rico Mayaguez and collaborators at hospitals affiliated with Harvard Medical School.

The program combines the interdisciplinary expertise of world-renowned faculty members in 11 departments at 3 Universities, collaborating with researchers at teaching hospitals and industry. Students enrolled in a Ph.D. program in Biology, Chemistry, Physics, Chemical Engineering, Mechanical/Industrial Engineering, Electrical/Computer Engineering, or Pharmaceutical Sciences (Northeastern University), Materials Science and Engineering or Integrative Biosciences (Tuskegee University), Applied Chemistry or Chemical Engineering (UPRM) may apply to the IGERT interdisciplinary program. The IGERT fellow will graduate with a Ph.D. degree in their core subject with specialization in Nanomedicine Science and Technology.

Download the IGERT Nanomedicine e-book summarizing the achievements of the Northeastern University IGERT Nanomedicine program

See original here:
IGERT Nanomedicine at Northeastern University

Nanotechnology in Medicine – Nanomedicine

The use of nanotechnology in medicine offers some exciting possibilities. Some techniques are only imagined, while others are at various stages of testing, or actually being used today.

Nanotechnology in medicine involves applications of nanoparticles currently under development, as well as longer range research that involves the use of manufactured nano-robots to make repairs at the cellular level (sometimes referred to as nanomedicine).

Whatever you call it, the use of nanotechnology in the field of medicine could revolutionize the way we detect and treat damage to the human body and disease in the future, and many techniques only imagined a few years ago are making remarkable progress towards becoming realities.

One application of nanotechnology in medicine currently being developed involves employing nanoparticles to deliver drugs, heat, light or other substances to specific types of cells (such as cancer cells). Particles are engineered so that they are attracted to diseased cells, which allowsdirect treatment of those cells. This technique reduces damage to healthy cells in the body and allows for earlier detection of disease.

For example, nanoparticles that deliver chemotherapy drugs directly to cancer cells are under development. Tests are in progress for targeted delivery of chemotherapy drugs and their final approval for their use with cancer patients is pending. One company, CytImmune has published the results of a Phase 1 Clinical Trial of their first targeted chemotherapy drug and another company, BIND Biosciences, has published preliminary results of a Phase 1 Clinical Trial for their first targeted chemotherapy drug and is proceeding with a Phase 2 Clinical Trial.

Researchers at the University of Illinois have demonstated that gelatin nanoparticles can be used to deliver drugs to damaged brain tissue.

Researchers at MIT using nanoparticles to deliver vaccine.The nanoparticles protect the vaccine, allowing the vaccine time to trigger a stronger immune response.

Reserchers are developing a method to release insulin that uses a sponge-like matrix that contains insulin as well as nanocapsules containing an enzyme. When the glucose level rises the nanocapsules release hydrogen ions, which bind to the fibers making up the matrix. The hydrogen ions make the fibers positively charged, repelling each other and creating openings in the matrix through which insulin is released.

Researchers are developing a nanoparticle that can be taken orally and pass through the lining of the intestines into the bloodsteam. This should allow drugs that must now be delivered with a shot to be taken in pill form.

Researchers are also developing a nanoparticle to defeat viruses. The nanoparticle does not actually destroy viruses molecules, but delivers an enzyme that prevents the reproduction of viruses molecules in the patients bloodstream.

Read the original post:
Nanotechnology in Medicine - Nanomedicine